Spleen size ranks among the most important risk factors in chronic myeloid leukemia (CML), but the pathogenic mechanisms of splenic hematopoiesis in CML remain poorly defined. Here, we studied the biology of Bcr --Abl positive leukemia-initiating cells in the spleen, using an inducible transgenic mouse model of CML. Disease kinetics showed greater increases of immature leukemic cells in spleen vs bone marrow (BM). To assess how Bcr --Abl alters the behavior of spleen-derived CML cells, we transplanted these cells either before ('pre-uninduced') or 44 days after ('pre-induced') expression of the oncogene. Mice transplanted with pre-induced spleen cells showed significantly increased neutrophilia and splenomegaly compared with mice receiving pre-uninduced spleen cells, suggesting that Bcr --Abl expression in the donors had increased splenic tumor burden. However, pre-induction also altered the biology of these cells, as shown by a striking increase in erythropoietic potential. These results differ from those of BM-derived CML stem cells where pre-induction of Bcr --Abl had previously been shown to decrease disease transplantability. Moreover, splenic cells were less sensitive to imatinib than BM cells. In conclusion, Bcr --Abl alters the biology of splenic leukemic stem cells by a cell-autonomous mechanism, but the disease phenotype is also influenced by the microenvironment of these cells.
INTRODUCTION
Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by the reciprocal translocation t(9;22) that arises in the hematopoietic stem cell (HSC) population. 1, 2 Although very impressive results have been obtained with tyrosine kinase inhibitors for the treatment of patients with CML, 3 --5 response to antileukemic treatment is hampered by Bcr --Abl independent effects or Bcr --Abl mutations and decreased tyrosine kinase inhibitor effectiveness upon disease progression. 6 In addition, CML stem cells persist in the vast majority of CML patients during tyrosine kinase inhibitor treatment 7 --9 due to lack of oncogene addiction of the stem cells. 10, 11 These CML stem cells are presumably responsible for relapses of the disease, which occur in the vast majority of patients that discontinue tyrosine kinase inhibitor treatment. 12 --14 However, the exact localization and organ distribution, in particular in bone marrow (BM) vs spleen, of these CML stem cells in the patient is unknown.
Splenomegaly, most likely because of extramedullary hematopoiesis, remains one of the most important prognostic factors in CML patients at diagnosis. 15 --18 Importantly, along with the basophil count, clinical assessment of spleen size is also the most important predictive factor for achievement of complete cytogenetic remission after 18 months of treatment with imatinib. 19 However, the underlying pathogenetic mechanism for this adverse prognostic impact of the spleen size has not been elucidated. More specifically, it is not clear whether the negative impact of splenomegaly is simply owing to a large leukemic burden or to a specific biology, which may be different in leukemic spleen cells as compared with BM-derived cells.
We have previously developed a transgenic SCLtTA/Bcr --Abl mouse model in which the expression of Bcr --Abl occurs upon removal of tetracycline primarily within the HSC compartment. 20 These mice develop a myeloproliferative syndrome which closely mimics the chronic phase of CML. We subsequently showed that the disease is transplantable using unfractionated BM cells or Lin À c-kit þ Sca-1 þ (LSK) cells. 10 In order to answer the question whether Bcr --Abl expression before transplant enhances the CML phenotype in the recipient mice, we had compared the disease phenotype in mice that had received BM cells from donors that had been induced to express Bcr --Abl for three weeks before transplant (pre-induced donors) with cells from uninduced donors. 10 These experiments showed that the CML phenotype was not enhanced regardless of whether pre-induced or pre-uninduced donor cells were used. In addition, serial transplantation of BM cells dramatically reduced the disease phenotype in secondary (21) recipients. 10 In order to study the role of leukemic spleen cells in CML, we here analyzed the effects of Bcr --Abl expression on the kinetics of CML development in BM vs spleen at varying time points after Bcr --Abl induction. In addition, we assessed the quality of leukemic spleen cells in different settings of serial spleen cell transplantation assays. Finally, we analyzed the response to imatinib therapy in spleen cells compared with BM-derived cells in this mouse model. Our results suggest that leukemic spleen cells contribute to CML development already at early stages, possess a higher leukemic potential, and are less affected by imatinib treatment than their BM counterparts.
MATERIALS AND METHODS

Real-time quantitative RT-PCR (Q-PCR)
Isolation of RNA from BM and spleen was performed using RNeasy Mini Kit (Qiagen, Hilden, Germany), followed by cDNA synthesis and real-time Q-PCR as described previously. 10 
Mice and genotyping
Genotyping of SCLtTAxBcr --Abl (dtg), SCLtTA single transgenic (stg), and Bcr --Abl (stg) mice was described previously. 10, 20 Twelve-week-old wildtype FVB/N recipients were purchased from Charles River Laboratories (Charles River Laboratories, Inc., Wilmington, MA, USA). Approval for animal research was obtained from the local authorities of North RhineWestphalia.
Spleen or BM cell transplantation
Spleen or BM cells were harvested from the spleen or femur and tibia of dtg and control mice (SCLtTA stg, Bcr --Abl stg or wt) and injected into the tail veins of 12-week-old FVB/N CD45.2 wild-type mice after AKC-treatment for lysis of mature erythrocytes. For transplantation of BM or spleen LSK cells, 1300 fluorescence-activated cell sorter (FACS) sorted cells were used for injection either along with 1 Â 10 5 wt FVB/N CD45.2 spleen cells (for transplantation of wt LSK cells only) or along with 6.36 Â 10 5 dtg non-LSK cells from BM or spleen (for transplantation of dtg LSK cells dtg non-LSK cells from the opposite organ were added). For isolation of non-LSK cells lineage positive cells were isolated by magnetic cell sorting using lineage cell depletion Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and were combined with FACS sorted cells gated for non-LSK cells. Donor mice had either been induced by tetracycline withdrawal for the advertised time frame before spleen or BM cell harvest or never been induced. All recipients were irradiated before transplantation using 8 Gy. For infection prophylaxis mice were treated with cotrimoxazole (Ratiopharm, Ulm, Germany) until 2 weeks after transplant.
Analysis and non-invasive monitoring of disease
Peripheral blood (PB) was collected from the retro-orbital plexus. The number of white blood cells was determined using a Hemavet counter (Drew Scientific Inc, Dallas, TX, USA).
Flow cytometry analysis PB, BM and spleen cells were isolated as described previously. 20 Lysis of enucleated red blood cells was achieved by applying AKC buffer. After washing, cells were analyzed using a FACS Calibur or FACS Aria cytometer (BD Biosciences, Heidelberg, Germany) after incubation with the following antibodies: murine CD3, B220, Gr-1, CD41, Ter119, IgG2a and IgG2b (BD Biosciences, Franklin Lakes, NJ, USA) and CD11b (Caltag/Invitrogen, Karlsruhe, Germany).
Multicolor FACS analysis of HSCs
For analysis of LSK cells, red blood cell-lysed BM and spleen cells were stained with tricolor-conjugated rat antibodies specific for the following lineage markers: CD3, CD4, CD8a, CD45R (B220) and Ly-6G (Gr-1) (Caltag/ Invitrogen, Karlsruhe, Germany), CD11-b, Ter119 (eBioscience, San Diego, CA, USA). LSK cells were identified using CD117 (c-kit)-allophycocyanin (APC), Sca-1 (Ly-6A/E)-biotin, anti-streptavidin-PE-Cy7, (BD Biosciences, Franklin Lakes, NJ, USA) antibodies.
Colony-Forming Unit (CFU) assay for BM and spleen CFU assays were performed in Methocult M3434 methylcellulose (Stem cell Technologies, Vancouver, Canada). 35 mm plates were prepared in triplicates containing 2 Â 10 4 BM or 1 Â 10 5 spleen cells (to account for a lower number of CFU-forming cells in the normal spleen as compared with BM) in 1 ml of methylcellulose each. Numbers of CFU were determined 9 days after plating.
Statistical analysis
Statistical analyses were performed using Student's t-test (normal distribution) or Mann--Whitney U test (when normal distribution was not given). Po0.05 was considered statistically significant. Graphs depict mean ± s.e.m.
RESULTS
Mature leukemic cells expand early during the course of CML-like disease in both BM and spleen We previously generated tet-off inducible transgenic mice reversibly expressing Bcr --Abl under the control of the SCL 3 0 enhancer, and these mice develop a chronic phase CML-like disease. 20 Here, we studied the kinetics of the disease in BM vs spleen during 7, 14, 21 and 28 days of Bcr --Abl induction. FACS analysis of BM-derived cells and spleen cells showed a significant increase of the percentage of Gr1/CD11b positive granulocytic cells in dtg (Bcr --Abl) vs control mice14 and 21 days after Bcr --Abl induction in spleen and BM, respectively (Supplementary Figure  S1 and S2). Although the early increase in splenic neutrophils was shown to be progressive, increase in BM neutrophils was still variable. The expansion of neutrophils in BM was associated with a decrease of B220-expressing B cells and Ter119-expressing erythrocytic cells, whereas erythrocytic cells were increased in the spleen of dtg mice (Supplementary Figures S1 and S2 ). Bcr --Abl mice developed splenomegaly as early as 7 days after oncogene induction (Supplementary Figure S3 ). This is due to an increase in total spleen cell number, as demonstrated by the correlation of spleen size and cell number in a cohort of nine mice (data not shown; y ¼ 28.449x --103. 26 Figure S4) . In contrast, the total number of B cells and CD3-expressing T cells in spleen was unaffected by the presence of Bcr --Abl. Oncogene-dependent progressive infiltration of myeloid cells into the spleen was confirmed by NACE staining (Supplementary Figure S5) . Expression of Bcr --Abl in dtg mice was shown by quantitative RT-PCR analysis in BM and spleen (Supplementary Figure S6) .
Immature leukemic cells predominantly expand in the spleen We previously showed that the CML-like disease is conferred upon transplantation of BM-derived LSK cells and that thus these cells contain the leukemia-initiating cell population. 10 We next wanted to follow the kinetics of immature CML cells in BM vs spleen and analyzed the fraction of CFUs and LSK cells in both organs. Although the CFU potential of BM-derived cells did not increase within the first 28 days of Bcr --Abl induction (Figure 1a) , spleen cells showed a significant twofold increase in CFU activity starting from day 21 of oncogene expression and progressed to threefold on day 28 ( Figure 1b ). This effect was even more pronounced when we calculated the total number of CFUs in the spleen, demonstrating a significant threefold increase as early as day 14 that further progressed dependent on continuous Bcr --Abl expression up to 12-fold on day 28 ( Figure 1c ). In addition, FACS analyses revealed that while the LSK cell population was only increased 1.5-fold in BM, spleen LSK cells increased 5-to 10-fold (Figures 1d and e) .
Bcr --Abl expression before transplantation increases the leukemic potential of spleen cells We previously demonstrated that the ability of BM-derived cells to induce leukemia upon transplantation is not enhanced upon pre-induction of Bcr --Abl expression in the donor mice before transplant. 10 Here, we studied whether the leukemic potential of spleen cells is altered by Bcr --Abl expression. Therefore, we transplanted 2 Â 10 6 spleen cells isolated from SCLtTA/Bcr --Abl dtg and control mice that had either been taken off tetracycline for 44 days to induce Bcr --Abl expression before spleen cell transplantation (primary induced; pre-induced) or that had never been taken off tetracycline before transplant (primary uninduced; pre-uninduced). All recipients were maintained off tetracycline to allow Bcr --Abl expression in dtg mice. Donor and recipient cells were distinguished by their respective CD45 isoform, with donor cells expressing CD45.1 and recipient cells expressing CD45.2. PB of recipient mice was analyzed 21 days after transplantation and showed similar engraftment levels of transplanted dtg myeloid spleen cells by CD45.1/Gr1 positivity (55.94% ± 8.81 and 42.40% ± 22.55; P ¼ 0.387 in Bcr --Abl expressing pre-uninduced and pre-induced mice, respectively; data not shown). Levels of CD45.1 positive cells were similar, suggesting that almost all of the transplanted cells in PB at this time point were derived from the myeloid lineage. All mice were killed for analysis 69 days after spleen cell transplantation. FACS analysis of BM cells showed a significant increase in immature granulocytic cells (Gr1 low /CD11b) and immature donor granulocytic cells (Gr1 low /CD45.1) in dtg transplanted mice regardless of whether donor mice had been pre-induced or not (Figure 2a ). However, expansion of total granulocytes and total donor granulocytes (Gr1/CD45.1) as well as the decrease of erythroid cells compared with controls was restricted to mice transplanted with pre-induced but not preuninduced spleen cells ( Figure 2a) . As a consequence, the extent of granulocytic expansion and the decrease of erythrocytes was significantly enhanced in pre-induced vs pre-uninduced dtg mice. Differences between pre-induced and pre-uninduced dtg spleen cell transplanted mice were even more prominent in the spleen: there was a significant increase in immature and total donor granulocytes in pre-induced spleen cell transplanted mice compared with pre-uninduced spleen cell transplanted mice (Figures 2b). Similar to the primary transgenic mice (Supplementary Figure S3 ), we observed an increase of erythrocytic cells in the spleen. The erythrocytic precursors (Ter119/CD45.1) were increased 2.6-fold in pre-induced and pre-uninduced dtg transplanted mice compared with controls and were donor-derived as demonstrated by CD45.1 positivity (Figure 2b ). Spleen weight of all mice was measured upon autopsy and showed that mice transplanted with dtg pre-induced spleen cells showed a significant 2.4-fold increase in spleen weight, whereas the increase of spleen weight in mice transplanted with dtg pre-uninduced spleen cells was less pronounced and not significant (Figure 2c ). Comparison between both dtg recipient groups showed that transplantation of pre-induced spleen cells resulted in a significant higher spleen weight than the transplantation dtg pre-uninduced spleen cells. Moreover, we analyzed the absolute numbers þ /c-kit þ ) was carried out by FACS of BM and spleen cells, 28 days after Bcr --Abl induction and is presented as percent of total living. (e) Total LSK number per spleen was calculated 28 days after Bcr --Abl induction, using percent of total LSK cells and total spleen cell count. All data are shown as mean ± s.e.m. *Po0.05. (Figure 2d ) of spleen LSK cells. While there was a 4.6-fold increase in LSK number upon transplantation of dtg pre-uninduced spleen cells compared with controls, mice transplanted with dtg preinduced spleen cells showed a 9.1-fold increase ( Figure 2d) . As a consequence, the number of LSK cells in dtg pre-induced transplanted mice was significantly higher as compared with the dtg pre-uninduced transplanted mouse group. LSK cells were predominantly donor-derived (Supplementary Figure S7) and thus the increase in dtg total LSK cells was mainly due to the increase of CD45.1-positive donor LSK cells (Figure 2e ). Histological analysis showed myeloid cell infiltration into the spleen and liver of dtg transplanted mice (Supplementary Figure S8) being more prominent in dtg pre-induced spleen cell transplanted mice compared with recipients of dtg pre-uninduced spleen cells. Finally, the difference in the severity of the CML-like phenotype was reflected by a significant 2.9-fold increase of Bcr --Abl level in the spleen of mice transplanted with dtg pre-induced vs pre-uninduced spleen cells (data not shown).
Secondary transplantation shows an altered biology of leukemic stem cells in the spleen of pre-induced mice We have previously shown that SCLtTA/Bcr --Abl derived BM cells lose their leukemic potential to induce CML upon serial transplantation, indicating that they had lost significant selfrenewal capacity. 10 In order to assess the long-term leukemic potential of spleen cells we re-transplanted spleen cells from the above-described primary recipients 69 days after their first transplantation. For re-transplantation, 2 Â 10 6 spleen cells (after red cell lysis), isolated from mice initially transplanted with dtg pre-induced spleen cells or dtg pre-uninduced spleen cells, were injected into 8Gy-irradiated FVB/N secondary recipients. Given that 55% (±11%) and 53% (±8%), resp., of the spleen cells were CD45.1 positive, the absolute number of transplanted CD45.1 positive cells was 1.10 Â 10 6 of dtg pre-uninduced and 1.08x10 6 of dtg pre-induced spleen cells (Table 1) . Analysis of PB was carried out 63 days after 21 spleen cell transplantation and showed a Spleen cell biology in CML M Schemionek et al significant increase of donor granulocytes in mice transplanted with dtg pre-induced spleen cells compared with dtg preuninduced recipients (Figure 3a ). All mice were killed for analysis 85 days after 21 transplantation. FACS analysis showed a minor but significant increase of total and immature donor granulocytes in the spleen (Figure 3b ), but not BM (data not shown) of dtg preinduced secondary recipients compared with pre-uninduced secondary recipients. However, interestingly, erythrocytic cells were dramatically increased in the spleen of dtg pre-induced vs pre-uninduced secondary recipients, with more than 50% being (Figure 4a and b) . Interestingly, upon transplantation of dtg spleen LSK þ BM non-LSK cells erythroid cells were again massively expanded in the spleen, whereas transplantation of BM LSK with spleen non-LSK cells only led to mild expansion of these cells (Figure 4b ). However, one has to take into account that the co-transplantation of spleen LSK and BM non-LSK cells did increase the engraftment that was achieved by control spleen LSK cells alone as shown by CD45.1 positive cells in BM and spleen (Figure 4a and b) . In contrast, the combination of spleen non-LSK and BM LSK cells did not significantly increase engraftment as it was achieved by control BM LSK cells alone, which suggest that engraftment of spleen non-LSK cells was poor.
Next we wanted to assess if the combination of total spleen (tspleen) and BM (tBM) cells could further alter the phenotype. Therefore, we again induced primary mice for 4 weeks and confirmed disease development by spleen weight (dtg: 384.5 mg±99.35 vs controls: 148.25 mg±17.13). Recipients were transplanted using either 2 Â 10 6 tBM cells or 1 Â 10 6 tBM cells in combination with 1 Â 10 6 tspleen cells from dtg or control mice. Neutrophilia and splenomegaly were present in Bcr --Abl positive tBM and tBM þ tspleen cell transplanted mice, 50 days after transplantation (Figures 4d, e and Supplementary Figure S10) . However, in addition, neutrophilia was significantly increased in mice receiving combined tBM and tspleen cells in comparison with tBM cells only, although transplanted cell numbers were identical in both groups.
Imatinib is less effective on leukemic spleen cells compared with BM cells Splenomegaly is associated with a poor prognosis in CML patients. 16, 17 To study the therapeutic success of CML therapy on BM vs spleen cells, we extended our analysis of cohorts of mice treated with imatinib or water as previously described 10 for the response of different cell subpopulations from BM and spleen. Engraftment of transplanted cells was confirmed by FACS analysis 27 days after bone marrow transplantation and showed CD45.1 positivity of 83.4 ± 3.2% in BM and 61.8 ± 5.7% in spleen of dtg mice (n ¼ 3) and 85.9±14.6% in BM and 70.8±6.2% in spleen of the controls (n ¼ 3). Mice were then treated with either imatinib or water by oral administration. Mice were killed for analysis 32 days after initiation of treatment. Donor (CD45.1) BM cells were shown to be significantly increased in water-treated dtg mice compared with controls. However, donor cells in imatinib-treated mice were decreased to control levels (Figure 5a) . Moreover, the increase in granulocytes that was due to an increase in mature donor granulocytes (Gr1 high /CD45.1) in water-treated dtg mice was completely reverted upon imatinib treatment. Contrary to BM, imatinib-treated mice still showed a significant increase of mature leukemic spleen cells compared with controls, and this was true regardless whether total numbers (Figure 5b ) or the percentage (data not shown) were calculated. The decrease of CD45.1 positive donor spleen cells in dtg imatinib-treated mice was accompanied by an increase of Ter119 positive cells and is thus not due to a therapeutic success but is caused by the increase of CD45 negative erythrocytes (Figure 5b) . Splenomegaly was only mildly affected by imatinib treatment within 32 days, showing a 2.6-fold increase in dtg water-treated mice and a 1.6-fold increase in imatinib-treated mice, compared with respective controls (Figure 5c ). Expression of Bcr --Abl was only slightly, but not significantly, decreased in BM or spleen of imatinib-treated mice (data not shown).
DISCUSSION
Enlargement of the spleen remains an adverse prognostic factor in CML patients both at diagnosis 16, 17 and during imatinib treatment, but the exact role of the spleen in the pathogenesis and maintenance of CML is still incompletely understood. Several clinical trials have been conducted to investigate whether targeting the spleen in CML may alter the course of the disease. Although prolonged complete remissions have in fact been documented in the past using splenectomy in patients with CML, 21, 22 these reports are anecdotal and have not led to implementation of splenectomy into the standard treatment of CML. However, these individual successes do suggest that the spleen can be the major site of disease in selected patients.
By applying an inducible transgenic CML mouse model we demonstrated that expansion of immature leukemic cells predominantly occurs in the spleen but only to a minor extent in the BM showing qualitative differences between BM and spleen cells (Figure 1 ). These differences were confirmed in our transplant experiments which showed that Bcr --Abl expression in spleen cells before transplant enhanced their leukemic potential (Figure 2) , despite similar engraftment levels 21 days after transplantation. The increased leukemic potential was not observed upon transplantation of pre-induced BM-derived cells. 10 Moreover, adding tspleen cells to tBM cells increases the leukemic potential. Results by others using the same mouse model showed that, upon intrafemoral injection, BM-derived Bcr --Abl positive LT --HSCs predominantly home to the spleen suggesting that our observations at least in part might be due to the homing properties of BM cells. 23 To analyze whether leukemic environmental conditions besides homing properties influence the potential of leukemic stem cells, we combined spleen or BM LSK cells with non-LSK cells from the opposite organ. These data again suggest that spleenderived CML stem cells are more potent than their BM-derived counterpart and that this is not due to support by spleen-derived more mature hematopoietic cells. However, engraftment of spleen non-LSK cells was poor, whereas BM non-LSK cells showed a better engraftment. Thus, we cannot exclude the possibility that residential spleen non-LSK cells have a role in leukemogenesis in a non-transplant setting. Our data also show a close collaboration between splenic CML stem cells and mature cells derived from BM.
Bcr --Abl expression primes spleen LSK cells towards reinforced erythrocytic differentiation as shown by a marked increase in mature and immature erythrocytic cells after serial transplantation of pre-induced tspleen cells or transplantation of pre-induced spleen LSK cells (Figures 3b and 4b) . Such phenotypic changes were neither seen with serially transplanted BM cells (Schemionek et al 10 and unpublished results) nor with induced BM LSK cells. This shows that, on the one hand, cell-autonomous erythrocytic priming by Bcr --Abl is restricted to leukemic spleen cells. On the other hand, the fate of these cells is also influenced by the environment because transplanted spleen cells were present in the BM and spleen, but erythropoiesis was only enhanced in the spleen. Finally, imatinib treatment of leukemic mice showed that spleen cells were less sensitive to imatinib than BM cells ( Figure 5 ). Interestingly, imatinib concentration upon oral administration to mice is 5-fold higher in spleen as compared with plasma, 24 suggesting that increased imatinib resistance of leukemic spleen cells is not due to lower drug concentrations but rather to a higher level of drug resistance in spleen cells. Together, these results clearly show significant differences in the biological properties of spleen-vs BM-derived Bcr --Abl positive cells. They also suggest that, in patients with CML, the negative prognostic impact of splenomegaly is not simply due to a larger tumor burden but that it also reflects disease biology.
Early histological studies found increased basophils and erythrocytic precursors in the spleen as compared with BM in patients with untreated CML. 25 The erythrocytic increase is similar to our findings in Bcr --Abl positive mice. To exclude a reactive process, we assessed Bcr --Abl expression in FACS-sorted Ter119 positive cells and confirmed that these cells expressed the oncogene (MS and SK, unpublished data). The propensity for erythrocytic differentiation was also described in Bcr --Abl transduced murine BM as well as human cord blood cells. 26, 27 At the same time, erythropoiesis was decreased in the BM in our Bcr --Abl positive mice, and this has been described for human CML as well 28 where both decreased BM erythropoiesis and increased spleen size are adverse prognostic factors. In addition, we observed an increased leukemic potential upon induction of Bcr --Abl expression in spleen cells before transplantation or transplantation of pre-induced spleen LSK cells combined with BM non-LSK cells compared with pre-induced BM LSK cells combined with spleen non-LSK cells. Together with data by others, 29 who found increased circulating spleen-derived cells in the same transgenic mouse model, these data support the idea that the spleen becomes a major site of leukemia-initiating cells upon disease development. This may be due to synergism between Bcr --Abl and the higher rate of cycling HSCs in spleen vs BM, as has been demonstrated for non-leukemic HSCs. 30 Interestingly, the number of CD45.2 positive non-leukemic recipient LSK cells were also increased in recipients receiving Bcr --Abl positive leukemic cells (Figure 2e ), indicating that these leukemic cells enhance proliferation of LSK cells, probably by secretion of growth factors as has been described previously. 31, 32 To our knowledge, this is the first report demonstrating that leukemia-initiating cells in the spleen show a different biology and a higher leukemic potential than BM-derived cells. The exact mechanism still has to be uncovered. However, our data suggest that cell-autonomous and extrinsic factors are both involved.
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